Quick answers
- What is Memantine and donepezil used for?
- The FDA-approved label (Namzaric, Allergan, Inc., March 6, 2026) says: “NAMZARIC is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. NAMZARIC is a combination of memantine hydrochloride, an NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor, indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Memantine and donepezil have a boxed warning?
- No. None of the 6 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Memantine and donepezil?
- The FDA drug shortage list shows “To be discontinued” for a product of this medicine (updated June 15, 2026). Ask your pharmacist about alternatives.
- Has Memantine and donepezil been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started March 15, 2021 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Memantine and donepezil?
- 6 companies list prescription products of Memantine and donepezil in the FDA NDC Directory, including Allergan, Inc., Amneal Pharmaceuticals NY LLC and Macleods Pharmaceuticals Limited.
What Memantine and donepezil is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
NAMZARIC is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. NAMZARIC is a combination of memantine hydrochloride, an NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor, indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized …
— FDA label: Namzaric, Allergan, Inc., effective March 6, 2026. Read the full label on DailyMed →
The FDA has 6 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 6 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Capsule, extended release · Capsule |
|---|---|
| Route | Oral |
| Prescription products | 14 in the FDA NDC Directory |
| Brand names | Memantine and Donepezil Hydrochlorides Extended-Release, Namzaric |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| donepezil hydrochloride 10 mg · memantine hydrochloride 14 mg capsule | Brand: Namzaric | $19.88 per capsule |
| donepezil hydrochloride 10 mg · memantine hydrochloride 14 mg capsule, extended release | Generic | $6.49 per capsule |
| donepezil hydrochloride 10 mg · memantine hydrochloride 21 mg capsule | Brand: Namzaric | $19.92 per capsule |
| donepezil hydrochloride 10 mg · memantine hydrochloride 28 mg capsule | Brand: Namzaric | $19.80 per capsule |
| donepezil hydrochloride 10 mg · memantine hydrochloride 28 mg capsule, extended release | Generic | $7.79 per capsule |
| donepezil hydrochloride 10 mg · memantine hydrochloride 7 mg capsule | Brand: Namzaric | $19.85 per capsule |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Allergan, Inc.4 products
- Amneal Pharmaceuticals NY LLC4 products
- Macleods Pharmaceuticals Limited2 products
- Vitruvias Therapeutics, Inc.2 products
- AvKARE1 product
- ANI Pharmaceuticals, Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA206439 NAMZARIC | Abbvie | December 23, 2014 | 3, latest July 18, 2016 2016: Efficacy · 2015: Manufacturing (CMC) · 2015: Manufacturing (CMC) |
Generic approvals (4)
- ANDA208328Amneal · January 27, 2017
- ANDA208237Ani Pharms · December 15, 2023
- ANDA208672Macleods Pharms · July 15, 2025
- ANDA216901Xiamen LP Pharm Co · July 15, 2025
Shortage status
To be discontinued · updated June 15, 2026 · first posted June 15, 2026
| Product | Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 14 mg (NDC 69238-1248-3) |
|---|---|
| Company | Amneal Pharmaceuticals |
Ask your pharmacist whether your product is affected and what the options are.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
March 15, 2021 · Class II · Terminated · D-0418-2021
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Namzaric (memantine HCl extended release and donepezil HCl) capsules 14 mg/10 mg per capsule 30 capsules Rx Only NDC 0456-1214-30 Distributed by Forest Pharmaceuticals, Inc. Subsidiary of Forest Laboratories, LLC. — Cardinal Health Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Namzaric, Allergan, Inc., effective March 6, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →